SCHEMBL4579407

SCHEMBL4579407

CCOC(=O)C=C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
LMNA P02545 4/20 0.50
MAPT P10636 2/20 0.50
ADORA1 P30542 1/20 0.50
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
ALDH1A1 P00352 3/20 0.47
MAPK1 P28482 2/20 0.47
PRMT1 Q99873 1/20 0.46
PKM P14618 1/20 0.46
ESR2 Q92731 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9538926 0.99 MEN1 (0.55) KMT2AMEN1LMNAMAPTADORA1
SCHEMBL31397280 0.95 MEN1 (0.52) KMT2AMEN1LMNAMAPTADORA1
SCHEMBL2831248 0.92 MEN1 (0.54) KMT2AMEN1LMNAMAPTADORA1
SCHEMBL8576896 0.92 MEN1 (0.54) KMT2AMEN1LMNAMAPTADORA1
SCHEMBL2831250 0.92 MEN1 (0.54) KMT2AMEN1LMNAMAPTADORA1
SCHEMBL6952558 0.87 MAPK1 (0.47) ALDH1A1MAPK1ESR2SMN1; SMN2
SCHEMBL14342045 0.87 POLB (0.52) KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL5036890 0.86 KMT2A (0.48) KMT2AMEN1LMNACYP3A4CYP2D6
SCHEMBL8542921 0.85 MEN1 (0.47) KMT2AMEN1LMNAMAPTADORA1
SCHEMBL8542919 0.85 MEN1 (0.47) KMT2AMEN1LMNAMAPTADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111868030-A Preparation method of 1- (1-tert-butyloxycarbonyl-4-piperidylacetyl) -4-methylsulfonyloxypiperidine and 1- (1-tert-butyloxycarbonyl-4-piperidylacetyl) -4-methylsulfonyloxypiperidine 有机合成药品工业株式会社 2020-10-30 CN claimed
US-20250340560-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BEIGENE SWITZERLAND GMBH (CH) 2025-11-06 US disclosed
US-20250034170-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2025-01-30 US disclosed
EP-4415706-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-08-21 EP disclosed
US-20240254128-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BEIGENE SWITZERLAND GMBH (CH) 2024-08-01 US disclosed
CN-111868030-B 1- (1-Tert-butoxycarbonyl-4-piperidylacetyl) -4-methanesulfonyloxy piperidine and preparation method thereof 有机合成药品工业株式会社 2024-07-19 CN disclosed
US-11827603-B2 Method for preparing 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine and 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine YUKI GOSEI KOGYO CO., LTD. (JP) 2023-11-28 US disclosed
US-11827603-B2 Method for preparing 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine and 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine YUKI GOSEI KOGYO CO., LTD. (JP) 2023-11-28 US disclosed
US-11827603-B2 Method for preparing 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine and 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine YUKI GOSEI KOGYO CO., LTD. (JP) 2023-11-28 US disclosed
CN-111868031-B Process for the preparation of N-alkoxycarbonylpiperidine derivatives and intermediates therefor 有机合成药品工业株式会社 2023-10-03 CN disclosed
US-20040063953-A1 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2004-04-01 US disclosed
EP-1400511-A1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI KOGYO CO., LTD. (JP) 2004-03-24 EP disclosed
US-20020119968-A1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents ZENECA LIMITED 2002-08-29 US disclosed
US-6225309-B1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents ZENECA LIMITED (GB) 2001-05-01 US disclosed
US-5965559-A STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE ZENECA LIMITED (GB) 1999-10-12 US disclosed
EP-0783500-B1 AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS ZENECA LTD (GB) 1998-07-22 EP disclosed
EP-0783500-A1 AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS ZENECA LIMITED (GB) 1997-07-16 EP disclosed
WO-1996010022-A1 AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS ZENECA LIMITED (GB) 1996-04-04 WO disclosed
US-4983614-A ANTISPASMODIC, ANTIALLERGENIC AND ANTIHISTAMINE AGENTS LES LABORATOIRES MERAM (FR) 1991-01-08 US disclosed
US-4289772-A PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 1981-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034170-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 KMT2A 3498/4885MEN1 4454/4885LMNA 2875/4885
US-20240254128-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BTK, LCK, SYK KMT2A 2628/4885MEN1 3923/4885LMNA 4691/4885
US-11827603-B2 Method for preparing 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine and 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine AP2A1, TERT, APEH KMT2A 739/4885MEN1 2255/4885LMNA 2486/4885
US-20020119968-A1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents SERPINC1, F2, SULT1E1 KMT2A 1699/4885MEN1 362/4885LMNA 412/4885
US-20040063953-A1 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound ORMDL3, MRPS18A, ACSL3 KMT2A 1972/4885MEN1 187/4885LMNA 3218/4885
US-20250340560-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS BTK, LCK, SYK KMT2A 2628/4885MEN1 3923/4885LMNA 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.